Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
The Role of Endoscopy in Gastrointestinal Cancers
share announcement

The Role of Endoscopy in Gastrointestinal Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: closed (30 December 2023) | Viewed by 6059

Special Issue Editors

Prof. Dr. Eduardo Redondo-Cerezo

E-Mail Website
Guest Editor
1. Department of Gastroenterology, Virgen de las Nieves University Hospital, 18014 Granada, Spain
2. School of Medicine, The University of Granada, Avda. de la Investigación 11, 18016 Granada, Spain
Interests: therapeutic endoscopy; pancreatic diseases; gastrointestinal bleeding; endoscopic ultrasonography; ERCP; epidemiology of gastrointestinal diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Julio Iglesias-Garcia

E-Mail Website
Guest Editor
Department of Gastroenterology, University Hospital of Santiago de Compostela, 15706 Santiago De Compostela, Spain
Interests: endoscopic ultrasonography; pancreatic diseases; gastrointestinal cancers; acute and chronic pancreatitis

Special Issue Information

Dear Colleagues,

Cancers is launching a Special Issue focused on the role of endoscopy in gastrointestinal cancers. Endoscopy has shifted from having a central, but still limited, role in diagnosis to an increasing and exciting participation in cancer therapy. At present, endoscopy has not only a central role in therapeutic decision-making in gastrointestinal cancer, but a direct therapeutic involvement in the treatment and palliation of these diseases. For these reasons, a journal Special Issue especially dedicated to GI endoscopy in cancer is timely.

We are pleased to invite you to send a manuscript for this Special Issue dealing with the role of endoscopy and endoscopic procedures in digestive cancers. In this sense, papers addressing the broad topic of endoscopy in gastrointestinal cancers, diagnostic or therapeutic, are welcomed. From purely diagnostic procedures to advanced therapeutic endoscopy, the range of possible manuscripts is wide.

This Special Issue aims to publish papers covering novelties for the diagnosis of early cancers, such as colorectal cancers, upper GI tract tumors and biliary-pancreatic disease, as well as insights into staging and endoscopy-based therapeutic alternatives that have arisen in this rapidly evolving field.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Early diagnosis and management of esophageal and gastric tumors;
  • Early diagnosis and screening of colorectal cancer;
  • Endoscopic management of upper GI tumors;
  • Staging of esophageal or gastric tumors;
  • Diagnosis and staging of pancreatic cysts and solid tumors;
  • Endoscopy’s role in biliary and pancreatic tumors: curative and palliative alternatives;
  • Endoscopy’s role in early cancer treatment;
  • Endoscopy’s role in the management of colorectal malignancies;
  • Screening of gastrointestinal and pancreatic cancers.

We look forward to receiving your submissions!

Prof. Dr. Eduardo Redondo-Cerezo
Dr. Julio Iglesias-Garcia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal neoplasms
  • endoscopy
  • endoscopic ultrasonography
  • therapeutic endoscopy
  • colorectal neoplasms
  • upper GI neoplasms
  • pancreatic tumors
  • pancreatic cysts

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

13 pages, 1792 KiB  
Article
Preoperative EUS vs. PET-CT Evaluation of Response to Neoadjuvant Therapy for Esophagogastric Cancer and Its Correlation with Survival
by Victor Amezcua-Hernandez, Rita Jimenez-Rosales, Juan Gabriel Martinez-Cara, Javier Garcia-Garcia, Francisco Valverde Lopez and Eduardo Redondo-Cerezo
Cancers 2023, 15(11), 2941; https://doi.org/10.3390/cancers15112941 - 27 May 2023
Viewed by 1409
Abstract
Background: The objective of our study was to investigate whether Endoscopic Ultrasonography (EUS) and Positron Emission Tomography-Computed Tomography (PET-CT) restaging can predict survival in upper gastrointestinal tract adenocarcinomas and to assess their accuracy when compared to pathology. Methods: We conducted a retrospective study [...] Read more.
Background: The objective of our study was to investigate whether Endoscopic Ultrasonography (EUS) and Positron Emission Tomography-Computed Tomography (PET-CT) restaging can predict survival in upper gastrointestinal tract adenocarcinomas and to assess their accuracy when compared to pathology. Methods: We conducted a retrospective study on all patients who underwent EUS for staging of gastric or esophago-gastric junction adenocarcinoma between 2010 and 2021. EUS and PET-CT were performed, and preoperative TNM restaging was conducted using both procedures within 21 days prior to surgery. Disease-free survival (DFS) and overall survival (OS) were evaluated. Results: A total of 185 patients (74.7% male) were included in the study. The accuracy of EUS for distinguishing between T1-T2 and T3-T4 tumors after neoadjuvant therapy was 66.7% (95% CI: 50.3–77.8%), and for N staging, the accuracy was 70.8% (95% CI: 51.8–81.8%). Regarding PET-CT, the accuracy for N positivity was 60.4% (95% CI: 46.3–73%). Kaplan–Meier analysis revealed a significant correlation between positive lymph nodes on restaging EUS and PET-CT with DFS. Multivariate COX regression analysis identified N restaging with EUS and PET-CT, as well as the Charlson comorbidity index, as correlated factors with DFS. Positive lymph nodes on EUS and PET-CT were predictors of OS. In multivariate Cox regression analysis, the independent risk factors for OS were found to be the Charlson comorbidity index, T response by EUS, and male sex. Conclusion: Both EUS and PET-CT are valuable tools for determining the preoperative stage of esophago-gastric cancer. Both techniques can predict survival, with preoperative N staging and response to neoadjuvant therapy assessed by EUS being the main predictors. Full article
(This article belongs to the Special Issue The Role of Endoscopy in Gastrointestinal Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

14 pages, 1398 KiB  
Review
Therapeutic Endoscopic Ultrasound for Complications of Pancreatic Cancer
by Samuel Han and Georgios I. Papachristou
Cancers 2024, 16(1), 29; https://doi.org/10.3390/cancers16010029 - 20 Dec 2023
Viewed by 1488
Abstract
Progression of pancreatic adenocarcinoma can result in disease complications such as biliary obstruction and gastric outlet obstruction. The recent advances in endoscopic ultrasound (EUS) have transformed EUS from a purely diagnostic technology to a therapeutic modality, particularly with the development of lumen-apposing metal [...] Read more.
Progression of pancreatic adenocarcinoma can result in disease complications such as biliary obstruction and gastric outlet obstruction. The recent advances in endoscopic ultrasound (EUS) have transformed EUS from a purely diagnostic technology to a therapeutic modality, particularly with the development of lumen-apposing metal stents. In terms of biliary drainage, EUS-guided choledochoduodenostomy and EUS-guided hepaticogastrostomy offer safe and effective techniques when conventional transpapillary stent placement via ERCP fails or is not possible. If these modalities are not feasible, EUS-guided gallbladder drainage offers yet another salvage technique when the cystic duct is non-involved by the cancer. Lastly, EUS-guided gastroenterostomy allows for an effective bypass treatment for cases of gastric outlet obstruction that enables patients to resume eating within several days. Future randomized studies comparing these techniques to current standard-of-care options are warranted to firmly establish therapeutic EUS procedures within the treatment algorithm for this challenging disease. Full article
(This article belongs to the Special Issue The Role of Endoscopy in Gastrointestinal Cancers)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

11 pages, 1783 KiB  
Systematic Review
Performance of the Fecal Immunochemical Test in Detecting Advanced Colorectal Neoplasms and Colorectal Cancers in People Aged 40–49 Years: A Systematic Review and Meta-Analysis
by Jen-Hao Yeh, Cheng-Hao Tseng, Wen-Lun Wang, Chih-I Chen, Yu-Peng Liu, Yi-Chia Lee, Jaw-Yuan Wang and Yu-Ching Lin
Cancers 2023, 15(11), 3006; https://doi.org/10.3390/cancers15113006 - 31 May 2023
Cited by 5 | Viewed by 2696
Abstract
Background: The incidence of early-onset colorectal cancer (CRC) is increasing. Many guidelines recommend initiating screening at 45 years. This study investigated the detection rate of advanced colorectal neoplasm (ACRN) by using fecal immunochemical tests (FITs) in individuals aged 40–49 years. Methods: PubMed, Embase, [...] Read more.
Background: The incidence of early-onset colorectal cancer (CRC) is increasing. Many guidelines recommend initiating screening at 45 years. This study investigated the detection rate of advanced colorectal neoplasm (ACRN) by using fecal immunochemical tests (FITs) in individuals aged 40–49 years. Methods: PubMed, Embase, and Cochrane Library databases were searched from inception to May 2022. The primary outcomes were the detection rates and positive predictive values of FITs for ACRN and CRC in people aged 40–49 (younger age group) and ≥50 years (average risk group). Results: Ten studies with 664,159 FITs were included. The FIT positivity rate was 4.9% and 7.3% for the younger age and average risk groups, respectively. Younger individuals with positive FIT results had significantly higher risks of ACRN (odds ratio [OR] 2.58, 95% confidence interval [CI] 1.79–3.73) or CRC (OR 2.86, 95% CI 1.59–5.13) than did individuals in the average-risk group, regardless of FIT results. Individuals aged 45–49 years with positive FIT results had a similar risk of ACRN (OR 0.80, 95% CI 0.49–1.29) to that of people aged 50–59 years with positive FIT results, although significant heterogeneity was observed. The positive predictive values of the FIT were 10–28.1% for ACRN and 2.7–6.8% for CRC in the younger age group. Conclusion: The detection rate of ACRN and CRC based on FITs in individuals aged 40–49 years is acceptable, and the yield of ACRN might be similar between individuals aged 45–49 and 50–59 years. Further prospective cohort and cost-effective analysis are warranted. Full article
(This article belongs to the Special Issue The Role of Endoscopy in Gastrointestinal Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop